Cue Biopharma (CUE) EBT (2017 - 2025)
Cue Biopharma (CUE) posted EBT of $2.0 million for Q4 2025, up 123.98% sequentially from -$8.2 million in Q3 2025, and up 121.36% YoY from $886344.6 in Q4 2024.
Cue Biopharma (CUE) EBT (2017 - 2025) Analysis & Trends
Cue Biopharma has reported EBT for 9 years, with the latest figure at $2.0 million in Q4 2025.
- Quarterly EBT rose 121.36% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$37.0 million (up 30.6% YoY) and the FY2025 annual result came in at -$27.5 million, up 40.48% from the prior year.
- EBT climbed to $2.0 million in Q4 2025 per CUE's latest filing, from -$8.2 million in the prior quarter.
- Over five years, EBT peaked at $2.0 million in Q4 2025 and troughed at -$18.8 million in Q1 2021.
- A 5-year average of -$12.4 million and a median of -$13.5 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT sank 91.08% in 2022, then soared 121.36% in 2025.
- Over 5 years, EBT stood at -$7.9 million in 2021, then tumbled by 91.08% to -$15.1 million in 2022, then grew by 12.72% to -$13.2 million in 2023, then surged by 30.22% to -$9.2 million in 2024, then jumped by 121.36% to $2.0 million in 2025.
- According to Business Quant data, EBT over the past three periods registered $2.0 million, -$8.2 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | Cue Biopharma | 150.85 Mn | 133.43 Mn | - | -87.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | -8.18 Mn |
| Jun 30, 2025 | -14.56 Mn |
| Mar 31, 2025 | -16.21 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -9.63 Mn |
| Jun 30, 2024 | -15.67 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Dec 31, 2023 | -13.16 Mn |
| Sep 30, 2023 | -12.13 Mn |
| Jun 30, 2023 | -13.66 Mn |
| Mar 31, 2023 | -13.71 Mn |
| Dec 31, 2022 | -15.08 Mn |
| Sep 30, 2022 | -11.16 Mn |
| Jun 30, 2022 | -13.30 Mn |
| Mar 31, 2022 | -14.33 Mn |
| Dec 31, 2021 | -7.89 Mn |
| Sep 30, 2021 | -14.30 Mn |
| Jun 30, 2021 | -10.30 Mn |
| Mar 31, 2021 | -18.83 Mn |